- Home
- GVH vs TOVX Comparison
GVH vs TOVX Comparison
Compare GVH & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVH
- TOVX
- Stock Information
- Founded
- GVH 2016
- TOVX 2001
- Country
- GVH Australia
- TOVX United States
- Employees
- GVH N/A
- TOVX N/A
- Industry
- GVH
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- GVH
- TOVX Health Care
- Exchange
- GVH Nasdaq
- TOVX Nasdaq
- Market Cap
- GVH 21.3M
- TOVX 3.8M
- IPO Year
- GVH 2023
- TOVX 2006
- Fundamental
- Price
- GVH $0.08
- TOVX $0.50
- Analyst Decision
- GVH Strong Buy
- TOVX Hold
- Analyst Count
- GVH 1
- TOVX 1
- Target Price
- GVH $0.40
- TOVX N/A
- AVG Volume (30 Days)
- GVH 107.2M
- TOVX 172.8K
- Earning Date
- GVH 02-12-2025
- TOVX 08-12-2025
- Dividend Yield
- GVH N/A
- TOVX N/A
- EPS Growth
- GVH 12.04
- TOVX N/A
- EPS
- GVH 0.09
- TOVX N/A
- Revenue
- GVH $16,540,178.00
- TOVX N/A
- Revenue This Year
- GVH N/A
- TOVX N/A
- Revenue Next Year
- GVH N/A
- TOVX N/A
- P/E Ratio
- GVH $0.83
- TOVX N/A
- Revenue Growth
- GVH N/A
- TOVX N/A
- 52 Week Low
- GVH $0.06
- TOVX $0.40
- 52 Week High
- GVH $1.82
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- GVH 22.31
- TOVX 51.01
- Support Level
- GVH $0.08
- TOVX $0.42
- Resistance Level
- GVH $0.09
- TOVX $0.48
- Average True Range (ATR)
- GVH 0.06
- TOVX 0.03
- MACD
- GVH -0.05
- TOVX 0.02
- Stochastic Oscillator
- GVH 1.45
- TOVX 82.80
About GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.